Profile: C. R. Bard, Inc. deals with products that focus on disease state management in three key areas namely vascular, urology and oncology. Our continence portfolio includes an array of options for the treatment of stress urinary incontinence and implants for pelvic floor reconstruction. Our Align® retropubic/suprapubic/retropubic-suprapubic (R/S/RS) urethral support system, Align® urethral support system is a suburethral sling device intended for the treatment of female stress urinary incontinence. The system comprises stainless steel introducers and a polypropylene mesh sling implant encased in a protective sheath with green guide tubes at each end of the sheath. The connectors are attached to the distal ends of the guide tubes, and are designed to attach to the tip portion of the introducer needles. They are terminally sterilized by ethylene oxide. Our Contigen® Bard® collagen implant is the least invasive implant option for the treatment of stress urinary incontinence (SUI). Its natural collagen protein adds bulk to surrounding urethral tissue to aid co-adaptation in a defective internal sphincter. It forms a soft network of fibers, inducing new tissue growth at the injection site. It is used successfully as a stand-alone therapy or concomitant therapy supporting surgical sling or pelvic re-constructive repairs.

The company was founded in 1904, has ~110 employees and is ISO 9001 certified. NYSE:BCR (SEC Filings)

FDA Registration Number: 1018233